Accelerating Research with Configurable Workflow, AI Assistants and FAIR Data
[Webinar] In this #GEN webinar, two experts, Prashant Vaidyanathan from Oxford Biomedica and Rob Brown, Vice President of Product and Presales from Sapio Sciences, discuss advancements in #configurable lab workflows, #AI#ChatGPT, and next-generation #labinformatics that are enabling novel discoveries in cell and gene therapy. You’ll learn how these tools accelerate workflow and #datamanagement strategies and #compliance principles that facilitate easy access and retrieval of scientifically meaningful data.
View the on-demand webinar below. |
That's the best news this week Mirabeau. They're the ones with the funds to drive it up. |
The Yanks have woken up |
HST
Bought in on Monday (as a turnaround company following the Covid hiccup and the company's repositioning) and appreciate yours and others contributions.
Tks |
Well hardly surprising. It needs to show chart support. There will be a dip in due course, otherwise no new base on which to build. |
 I've seen similar many times with OXB (and other companies) before and it reminds me of the old adage about the transfer of money from the impatient to the patient.
I'm easy about it and if people who bought in for the results are now taking a few quid out, well nobody ever made a loss taking a profit did they? Even if it is a small profit taken early vs what is on the table long term.
I mentioned the other day about Novartis (obviously a fantastic long term partner for us) and with each announcement it was 2 steps forward and 1 back until it sunk in with the people who matter that a commercial supply deal for them was worth a lot of money to OXB for a long time. You can see those Novartis dates in the long term chart and how the climb lags. Unfortunately covid and the world going mad knocked us down from the Novartis gains, then built us up with the AZ deal and then knocked us down again.
To dive back into my lucky dip of useful sayings, some days you're the pigeon, other days the statue.
Back to where we are and the words of the great philosopher Paul Tuttle Snr., "that was is what was but this is is what is now".
I'd hoped for better press coverage than what we got following the results. That may still be coming, but if it doesn't come soon then OXB need to make some news themselves. I'm actually quite confident that they can do that and of course there were mentions / hints in the webcast.
They listed 2 commercial supply partners, before explaining that it isn't really 2 just yet, it's Novartis + 1 undisclosed preparing for commercial production.
Just who that refers to (we have had many guesses here) doesn't really matter, but I do remember from Novartis and their submission for review, a really important part of the submission (nearly as important as the actual trial data) is proving that if you are granted a licence for a medicine then you can show that you have in place a proven capability to supply drug material immediately to meet the treated need (of that granted licence).
This is what OXB will be doing right now. So whichever regulator it is (MHRA / EMA / FDA) will either be auditing whichever OXB facility have prepared for this work or studying a presentation by OXB's in house QA/QC/Validation people submitted to cover the same thing.
So when the final data for our partner's drug goes before the regulator review committee (soon) part of that submission will be a guarantee of what amount OXB can supply by when and the standards it will meet. It may even have happened and they are simply waiting for the announcement.
Regardless of the if / but / when / where vagaries of that statement, very soon OXB have 2 commercial supply bankers where instead of one off batches for trial supply, they will produce batches continually to meet demand for the life of the drug. It's a big thing for OXB (and us).
On top of this we have Stuart admitting that they are talking about / looking at a couple of things outside of what we would normally do - and surely one of those has to be the long held presumption here of the malaria vaccine for Serum.
My only caution there (assuming our collective guesses are close) is that WHO > UNICEF > GAVI > Serum > OXB in a long line provides massive possibilities for that taking a lot longer than it needs to - but you never know.
An announcement about that would be game changing news for us, but to repeat something I've mentioned before - the only time I've ever seen these huge organisations rush something through was during covid. |
Feels like a period of consolidation for the near term. Let a few lock in short term profits. |
In my last corporate job I was contractually obligated to own company shares worth 300% of my base salary, and I was nowhere near CEO level! We were given 5 years to get to that level from the point where it became necessary, with schemes to convert bonuses to shares all counted in the mix. There will be something similar to that at OCB, I'm sure. To be honest, I'm never happy if executives have less than that sort of level of skin in the game, and 200% for a CEO feels light. My other conviction holdng is BUR, where the executives are very significant shareholders, and where shares for options etc are bought in the open market to avoid shareholder dilution. That's gold standard. |
Page 116 is worth a look as you can work out who has been buying / selling this year.
I would say that Vanguard and Mr Shah have likely just been diluted below 3% when IM received shares in payment for ABL, but the rest is straightforward to spot. |
Astonishing how much is in that report which is of no real relevance to OXB - and certainly not OXB shareholders (unless their name is Greta) - but I'm at page 97 now and have found a new one for me - in that Stuart and Frank are both obliged to hold shares to the value of 200% of their salary (Frank) and 175% (Stuart).
Frank has only met 7% of that so far, so if he doesn't buy some now (as cheap as they are likely to be) then maybe he can't? (i.e. the normal open period post results has something looming?). |
No, I'm pretty sure it's new shares printed by OXB in exchange for Eur20m in cash at a price yet to be determined. |
'In accordance with the terms of the transaction, Institut Mérieux intends to become a major shareholder in Oxford Biomedica and prior to today’s completion of the acquisition of ABL Europe had already built a stake of 3.3 per cent of the Company’s then issued share capital through purchases in the open market, with the intention of owning approximately 10.0 percent of the Company’s ordinary shares by the end of Q3 2024.'
--
So that's 3.2% plus 3.3% = 6.5%. So IM intend to buy in the open market another 3.5% before end Q3-2024. That's some buying to come in the open market. Can you imagine if decent news drops then you'll have private buyers and IM competing for stock |
That was you with the 3x 44044 then? ;)
Annual report is out |
I did get some earlier on - very tricky I know for the size, and now we are in auction no less so getting even harder at these much higher prices than before unless you want a few hundred....truly amazing response to the results and counter intuitive as you would expect profit taking to supply the market with shares :) |
I think the China thing is a mystery to us all red. In my lifetime they have gone from being a closed society who all dressed the same and were lucky if they had a state approved bicycle, to what they are today - where most things are fake (including some of their property bubble cities) - but 2nd largest economy in the world regardless.
The scale of the copying is unparalleled in history, but I think from the perspective of the CEO's, then as long as they are in with the correct people (partnership with someone who is in favour / very well connected) then getting something out a of a huge market is better than simply having your product copied in exchange for nothing.
Will the US actually do anything other than sabre rattling? Remains to be seen. |
What a lovely run since March +50% :-) |
The lack of liquidity for sellers must have been agony on the way down breaking through all the various stop losses, but can help a bit on the way up with various of us trying to add in where we can :) |
i’m no chartist but technical comment i’ve seen confirms very strong short term moving averages that suggests a pretty clear run to over 4 quid.More immediately though,i wouldn’t be surprised to see a bit of choppiness in the 280-300 range with the big figure representing resistance six months back. |
There's some structure between 290 - 330, hopefully we'll see a move through that then a pullback into that range to build support.I'm not looking to take a haircut until we're north of 410 all imo dyor ofc. |
I was aware of this; the Economist had an article a few weeks back detailing the various components of the US action on Chinese tech, and gene/ cell therapy was mentioned. A great deal (if not all) of western IP in the field will have already been 'transferred' to Chinese companies some way or other, but the shambles they made of COVID vaccines demonstrated that being able to copy a tech doesn't immediately mean that you can master it. The US action will restrict their being able to gain such mastery, in this and in other fields. They will catch up in time, but by then their commercial reach will have been curtailed somewhat. It should have been done 10 years ago when it became clear that China wouldn't play the free trade game fairly. I'm still astounded at the line of US/ German CEO's visiting China (Musk being the latest) keen to transfer yet more of their IP - and any remaining competitive advantage, home or away - to China. |
Pleased to see that unlike 'normal' behaviours, when an event gives the share price a lift the following day some profits are taken, we seem to have more buyers. Looking good. |
I'm no chartist but I am intrigued by the last question in the webcast about prospective US sanctions on WuXi Biologics.
I was blissfully unware of that one until yesterday, but I believe it to be very significant.
If there is a fudge / political trade done then it won't affect us at all, but if China is off limits for CDMO for a while then who fills the gap?
Remember Stuart's words yesterday - full is between 2x & 3x where we are now.
Hedge funds specialise in hedging bets don't they? Hence the name. Any with an interest in this sector are surely going to be looking to take their "What if?" positions. |
I guess based on the current trajectory we could easily reach £3.50 by mid May (or possibly sooner)
Market seems to be playing catch-up now as OXB proves it's doubters wrong. |
for any charting specialists who invest here, where do you see then first pause for breath ... |
Someone's accumulating |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
